In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: Results of a phase II study of P/DOCE chemotherapy

S. E. O'Reilly, J. M. Connors, S. Howdle, P. Hoskins, R. Klasa, Paul Klimo, D. S. Stuart

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Purpose: The results of a prospective, phase II trial of an 8-week treatment program consisting of epirubicin or doxorubicin, vincristine, cyclophosphamide, etoposide, and prednisone (P/DOCE) for elderly patients with advanced large-cell lymphoma are reported and compared with previous phase II studies conducted in similar patients at the same institution. Patients and Methods: Between March 1988 and September 1991, 63 previously untreated patients aged 65 to 85 years (median, 75) with advanced-stage diffuse large-cell lymphoma, defined as Ann Arbor stage III or IV or stage I or II with B symptoms or bulky disease, were enrolled on a brief, 8-week protocol consisting of five outpatient chemotherapy treatments. Results: The complete response (CR) rate was 62%. The treatment-related mortality rate was 8%, the actuarial 4-year failure-free survival (FFS) rate was 41%, and the overall survival (OS) rate was 45%. These results were compared with two earlier, 12-week protocols, low-dose doxorubicin, cyclophosphamide, vincristine, bleomycin, and prednisone (LD-ACOB-B) and etoposide, doxorubicin, bleomycin, and prednisone (VABE), performed at the same center. There was no difference in outcome among the three regimens. If all 133 patients treated on any one of these three specially designed regimen for elderly patients are combined, the projected 5-year OS rate is 38%. Conclusion: The 8-week P/DOCE chemotherapy regimen is equal in efficacy and similar in toxicity to 3 months of chemotherapy administered on a weekly schedule and similar to the results reported in the literature for longer, anthracycline-based chemotherapy treatments. There does not appear to be any improvement in outcome from more protracted treatment programs compared with the 8-week P/DOCE protocol.

Original languageEnglish (US)
Pages (from-to)2250-2257
Number of pages8
JournalJournal of Clinical Oncology
Volume11
Issue number11
DOIs
StatePublished - Jan 1 1993
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Drug Therapy
Prednisone
Doxorubicin
Survival Rate
Bleomycin
Vincristine
Etoposide
Cyclophosphamide
Therapeutics
Epirubicin
Anthracyclines
Lymphoma
Appointments and Schedules
Outpatients
Mortality

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma : Results of a phase II study of P/DOCE chemotherapy. / O'Reilly, S. E.; Connors, J. M.; Howdle, S.; Hoskins, P.; Klasa, R.; Klimo, Paul; Stuart, D. S.

In: Journal of Clinical Oncology, Vol. 11, No. 11, 01.01.1993, p. 2250-2257.

Research output: Contribution to journalArticle

O'Reilly, S. E. ; Connors, J. M. ; Howdle, S. ; Hoskins, P. ; Klasa, R. ; Klimo, Paul ; Stuart, D. S. / In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma : Results of a phase II study of P/DOCE chemotherapy. In: Journal of Clinical Oncology. 1993 ; Vol. 11, No. 11. pp. 2250-2257.
@article{5614e4d82fd242e88d932d1d35b5999b,
title = "In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: Results of a phase II study of P/DOCE chemotherapy",
abstract = "Purpose: The results of a prospective, phase II trial of an 8-week treatment program consisting of epirubicin or doxorubicin, vincristine, cyclophosphamide, etoposide, and prednisone (P/DOCE) for elderly patients with advanced large-cell lymphoma are reported and compared with previous phase II studies conducted in similar patients at the same institution. Patients and Methods: Between March 1988 and September 1991, 63 previously untreated patients aged 65 to 85 years (median, 75) with advanced-stage diffuse large-cell lymphoma, defined as Ann Arbor stage III or IV or stage I or II with B symptoms or bulky disease, were enrolled on a brief, 8-week protocol consisting of five outpatient chemotherapy treatments. Results: The complete response (CR) rate was 62{\%}. The treatment-related mortality rate was 8{\%}, the actuarial 4-year failure-free survival (FFS) rate was 41{\%}, and the overall survival (OS) rate was 45{\%}. These results were compared with two earlier, 12-week protocols, low-dose doxorubicin, cyclophosphamide, vincristine, bleomycin, and prednisone (LD-ACOB-B) and etoposide, doxorubicin, bleomycin, and prednisone (VABE), performed at the same center. There was no difference in outcome among the three regimens. If all 133 patients treated on any one of these three specially designed regimen for elderly patients are combined, the projected 5-year OS rate is 38{\%}. Conclusion: The 8-week P/DOCE chemotherapy regimen is equal in efficacy and similar in toxicity to 3 months of chemotherapy administered on a weekly schedule and similar to the results reported in the literature for longer, anthracycline-based chemotherapy treatments. There does not appear to be any improvement in outcome from more protracted treatment programs compared with the 8-week P/DOCE protocol.",
author = "O'Reilly, {S. E.} and Connors, {J. M.} and S. Howdle and P. Hoskins and R. Klasa and Paul Klimo and Stuart, {D. S.}",
year = "1993",
month = "1",
day = "1",
doi = "10.1200/JCO.1993.11.11.2250",
language = "English (US)",
volume = "11",
pages = "2250--2257",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma

T2 - Results of a phase II study of P/DOCE chemotherapy

AU - O'Reilly, S. E.

AU - Connors, J. M.

AU - Howdle, S.

AU - Hoskins, P.

AU - Klasa, R.

AU - Klimo, Paul

AU - Stuart, D. S.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Purpose: The results of a prospective, phase II trial of an 8-week treatment program consisting of epirubicin or doxorubicin, vincristine, cyclophosphamide, etoposide, and prednisone (P/DOCE) for elderly patients with advanced large-cell lymphoma are reported and compared with previous phase II studies conducted in similar patients at the same institution. Patients and Methods: Between March 1988 and September 1991, 63 previously untreated patients aged 65 to 85 years (median, 75) with advanced-stage diffuse large-cell lymphoma, defined as Ann Arbor stage III or IV or stage I or II with B symptoms or bulky disease, were enrolled on a brief, 8-week protocol consisting of five outpatient chemotherapy treatments. Results: The complete response (CR) rate was 62%. The treatment-related mortality rate was 8%, the actuarial 4-year failure-free survival (FFS) rate was 41%, and the overall survival (OS) rate was 45%. These results were compared with two earlier, 12-week protocols, low-dose doxorubicin, cyclophosphamide, vincristine, bleomycin, and prednisone (LD-ACOB-B) and etoposide, doxorubicin, bleomycin, and prednisone (VABE), performed at the same center. There was no difference in outcome among the three regimens. If all 133 patients treated on any one of these three specially designed regimen for elderly patients are combined, the projected 5-year OS rate is 38%. Conclusion: The 8-week P/DOCE chemotherapy regimen is equal in efficacy and similar in toxicity to 3 months of chemotherapy administered on a weekly schedule and similar to the results reported in the literature for longer, anthracycline-based chemotherapy treatments. There does not appear to be any improvement in outcome from more protracted treatment programs compared with the 8-week P/DOCE protocol.

AB - Purpose: The results of a prospective, phase II trial of an 8-week treatment program consisting of epirubicin or doxorubicin, vincristine, cyclophosphamide, etoposide, and prednisone (P/DOCE) for elderly patients with advanced large-cell lymphoma are reported and compared with previous phase II studies conducted in similar patients at the same institution. Patients and Methods: Between March 1988 and September 1991, 63 previously untreated patients aged 65 to 85 years (median, 75) with advanced-stage diffuse large-cell lymphoma, defined as Ann Arbor stage III or IV or stage I or II with B symptoms or bulky disease, were enrolled on a brief, 8-week protocol consisting of five outpatient chemotherapy treatments. Results: The complete response (CR) rate was 62%. The treatment-related mortality rate was 8%, the actuarial 4-year failure-free survival (FFS) rate was 41%, and the overall survival (OS) rate was 45%. These results were compared with two earlier, 12-week protocols, low-dose doxorubicin, cyclophosphamide, vincristine, bleomycin, and prednisone (LD-ACOB-B) and etoposide, doxorubicin, bleomycin, and prednisone (VABE), performed at the same center. There was no difference in outcome among the three regimens. If all 133 patients treated on any one of these three specially designed regimen for elderly patients are combined, the projected 5-year OS rate is 38%. Conclusion: The 8-week P/DOCE chemotherapy regimen is equal in efficacy and similar in toxicity to 3 months of chemotherapy administered on a weekly schedule and similar to the results reported in the literature for longer, anthracycline-based chemotherapy treatments. There does not appear to be any improvement in outcome from more protracted treatment programs compared with the 8-week P/DOCE protocol.

UR - http://www.scopus.com/inward/record.url?scp=0027520523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027520523&partnerID=8YFLogxK

U2 - 10.1200/JCO.1993.11.11.2250

DO - 10.1200/JCO.1993.11.11.2250

M3 - Article

C2 - 8229141

AN - SCOPUS:0027520523

VL - 11

SP - 2250

EP - 2257

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -